Citadel Advisors’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-14,000
| Closed | -$199K | – | 13371 |
|
|
2025
Q4 | $199K | Sell |
14,000
-44,400
| -76% | -$436K | ﹤0.01% | 11050 |
|
|
2025
Q3 | $460K | Sell |
58,400
-10,700
| -15% | -$76.2K | ﹤0.01% | 9344 |
|
|
2025
Q2 | $396K | Buy |
69,100
+15,100
| +28% | +$97.5K | ﹤0.01% | 9171 |
|
|
2025
Q1 | $441K | Buy |
54,000
+19,300
| +56% | +$179K | ﹤0.01% | 8754 |
|
|
2024
Q4 | $327K | Sell |
34,700
-3,800
| -10% | -$39.5K | ﹤0.01% | 9476 |
|
|
2024
Q3 | $411K | Sell |
38,500
-9,200
| -19% | -$100K | ﹤0.01% | 8681 |
|
|
2024
Q2 | $473K | Buy |
47,700
+26,800
| +128% | +$275K | ﹤0.01% | 8162 |
|
|
2024
Q1 | $246K | Sell |
20,900
-35,400
| -63% | -$453K | ﹤0.01% | 9897 |
|
|
2023
Q4 | $799K | Sell |
56,300
-8,000
| -12% | -$90.8K | ﹤0.01% | 7134 |
|
|
2023
Q3 | $782K | Buy |
64,300
+17,700
| +38% | +$228K | ﹤0.01% | 7088 |
|
|
2023
Q2 | $585K | Buy |
46,600
+5,200
| +13% | +$61.7K | ﹤0.01% | 7591 |
|
|
2023
Q1 | $459K | Sell |
41,400
-15,800
| -28% | -$195K | ﹤0.01% | 8490 |
|
|
2022
Q4 | $698K | Buy |
57,200
+29,000
| +103% | +$326K | ﹤0.01% | 7549 |
|
|
2022
Q3 | $294K | Buy |
28,200
+2,000
| +8% | +$22.3K | ﹤0.01% | 9625 |
|
|
2022
Q2 | $281K | Sell |
26,200
-5,100
| -16% | -$42K | ﹤0.01% | 9942 |
|
|
2022
Q1 | $296K | Sell |
31,300
-13,700
| -30% | -$128K | ﹤0.01% | 10629 |
|
|
2021
Q4 | $520K | Sell |
45,000
-160,300
| -78% | -$1.79M | ﹤0.01% | 9599 |
|
|
2021
Q3 | $1.96M | Buy |
205,300
+59,700
| +41% | +$611K | ﹤0.01% | 6399 |
|
|
2021
Q2 | $1.4M | Sell |
145,600
-93,200
| -39% | -$910K | ﹤0.01% | 7463 |
|
|
2021
Q1 | $2.36M | Buy |
238,800
+185,900
| +351% | +$2.88M | ﹤0.01% | 6016 |
|
|
2020
Q4 | $1.22M | Buy |
52,900
+25,600
| +94% | +$524K | ﹤0.01% | 6375 |
|
|
2020
Q3 | $385K | Sell |
27,300
-27,400
| -50% | -$399K | ﹤0.01% | 7729 |
|
|
2020
Q2 | $825K | Sell |
54,700
-24,800
| -31% | -$302K | ﹤0.01% | 6184 |
|
|
2020
Q1 | $735K | Buy |
79,500
+30,600
| +63% | +$291K | ﹤0.01% | 5851 |
|
|
2019
Q4 | $476K | Buy |
48,900
+5,700
| +13% | +$52.2K | ﹤0.01% | 6886 |
|
|
2019
Q3 | $346K | Sell |
43,200
-81,500
| -65% | -$885K | ﹤0.01% | 7351 |
|
|
2019
Q2 | $1.56M | Buy |
124,700
+112,900
| +957% | +$1.43M | ﹤0.01% | 4952 |
|
|
2019
Q1 | $160K | Sell |
11,800
-55,900
| -83% | -$683K | ﹤0.01% | 8356 |
|
|
2018
Q4 | $649K | Sell |
67,700
-11,900
| -15% | -$131K | ﹤0.01% | 5993 |
|
|
2018
Q3 | $962K | Buy |
79,600
+28,400
| +55% | +$397K | ﹤0.01% | 5627 |
|
|
2018
Q2 | $800K | Sell |
51,200
-332,000
| -87% | -$5.02M | ﹤0.01% | 5584 |
|
|
2018
Q1 | $5.76M | Buy |
383,200
+200,500
| +110% | +$3.05M | ﹤0.01% | 2315 |
|
|
2017
Q4 | $2.63M | Buy |
182,700
+21,400
| +13% | +$294K | ﹤0.01% | 3265 |
|
|
2017
Q3 | $2.43M | Buy |
161,300
+130,000
| +415% | +$1.72M | ﹤0.01% | 3187 |
|
|
2017
Q2 | $315K | Buy |
31,300
+900
| +3% | +$7.24K | ﹤0.01% | 5820 |
|
|
2017
Q1 | $217K | Sell |
30,400
-11,900
| -28% | -$75.2K | ﹤0.01% | 6383 |
|
|
2016
Q4 | $210K | Buy |
42,300
+11,500
| +37% | +$79.6K | ﹤0.01% | 6242 |
|
|
2016
Q3 | $228K | Buy |
30,800
+13,800
| +81% | +$93.2K | ﹤0.01% | 6123 |
|
|
2016
Q2 | $93K | Buy |
17,000
+3,800
| +29% | +$26.6K | ﹤0.01% | 6222 |
|
|
2016
Q1 | $112K | Buy |
13,200
+600
| +5% | +$4.25K | ﹤0.01% | 5978 |
|
|
2015
Q4 | $122K | Sell |
12,600
-500
| -4% | -$4.51K | ﹤0.01% | 6468 |
|
|
2015
Q3 | $183K | Sell |
13,100
-4,200
| -24% | -$65.9K | ﹤0.01% | 6263 |
|
|
2015
Q2 | $245K | Sell |
17,300
-35,700
| -67% | -$429K | ﹤0.01% | 6042 |
|
|
2015
Q1 | $577K | Buy |
53,000
+10,600
| +25% | +$93.4K | ﹤0.01% | 4699 |
|
|
2014
Q4 | $353K | Buy |
42,400
+8,000
| +23% | +$54.9K | ﹤0.01% | 5197 |
|
|
2014
Q3 | $205K | Buy |
+34,400
| New | +$180K | ﹤0.01% | 5696 |
|
|
2014
Q1 | – | Sell |
-8,400
| Closed | -$20K | – | 7890 |
|
|
2013
Q4 | $20K | Buy |
8,400
+2,000
| +31% | +$4.39K | ﹤0.01% | 6448 |
|
|
2013
Q3 | $15K | Sell |
6,400
-3,200
| -33% | -$8.03K | ﹤0.01% | 6346 |
|
|
2013
Q2 | $22K | Buy |
+9,600
| New | +$29.5K | ﹤0.01% | 6028 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Citadel Advisors's FOLD Position: Q1 2026 in Review
Citadel Advisors reduced its Amicus Therapeutics (FOLD) stake by 98% in Q1 2026, selling an estimated $71.3M and leaving 124,794 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #6294.
Citadel Advisors first reported a position in FOLD in Q2 2013 and has held it in 48 quarters since. The position peaked at $87.5M in Q1 2019. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Citadel Advisors held 124,794 shares of Amicus Therapeutics worth $1.8M as of Q1 2026.
- Citadel Advisors sold 4,972,002 Amicus Therapeutics shares in Q1 2026, an estimated $71.3M.
- Amicus Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6294 holding.
- Citadel Advisors first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 48 quarters since.
- Citadel Advisors's Amicus Therapeutics position peaked at $87.5M in Q1 2019.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.